Securities code: 002755 securities abbreviation: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Announcement No.: 2022-019 Beijing Aosaikang Pharmaceutical Co.Ltd(002755)
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (hereinafter referred to as “the company”) convened the 17th meeting of the 5th board of directors and the 16th meeting of the 5th board of supervisors on November 19, 2021, deliberated and adopted the proposal on continuing to promote the issue of shares and paying cash to purchase assets, It is proposed to continue to promote the purchase of 60% equity of Jiangsu weidekang Medical Technology Co., Ltd. by issuing shares and paying cash. For details, please refer to the announcement of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) on continuing to promote the issue of shares and paying cash to purchase assets (Announcement No.: 2021-088) issued by the company on November 20, 2021. The company has issued the progress announcement of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) on issuing shares and paying cash to purchase assets (Announcement No.: 2021-095) on December 18, 2021; On January 18, 2022, Beijing Aosaikang Pharmaceutical Co.Ltd(002755) announcement on the progress of issuing shares and paying cash to purchase assets (Announcement No.: 2022-002) was issued.
As of the disclosure date of this announcement, the company is coordinating relevant parties to actively promote the work related to this transaction in accordance with the audit opinions of the Audit Committee for mergers and acquisitions of listed companies of the CSRC and in combination with the actual situation. After the relevant work is completed, the company will perform the necessary decision-making and approval procedures in accordance with the relevant laws, regulations and the articles of association, And fulfill the obligation of information disclosure in time.
The information disclosure media designated by the company are securities times, securities daily and http://www.cn.info.com.cn, All information of the company shall be subject to the announcement published in the above designated media. There is still uncertainty in this transaction. Please pay attention to the follow-up announcement and pay attention to the investment risk.
It is hereby announced.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) board of directors February 17, 2022
